Your browser is no longer supported. Please, upgrade your browser.
Settings
CLVS Clovis Oncology, Inc. daily Stock Chart
CLVS [NASD]
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-4.24 Insider Own0.40% Shs Outstand54.55M Perf Week-11.73%
Market Cap2.47B Forward P/E- EPS next Y-2.16 Insider Trans-13.65% Shs Float47.08M Perf Month-15.60%
Income-184.20M PEG- EPS next Q-1.36 Inst Own- Short Float16.00% Perf Quarter-26.22%
Sales55.50M P/S44.52 EPS this Y56.90% Inst Trans-0.31% Short Ratio5.60 Perf Half Y-40.14%
Book/sh7.35 P/B6.16 EPS next Y54.00% ROA-47.30% Target Price86.90 Perf Year-22.75%
Cash/sh10.33 P/C4.38 EPS next 5Y- ROE-116.90% 52W Range44.83 - 99.45 Perf YTD-33.38%
Dividend- P/FCF- EPS past 5Y-5.70% ROI-27.30% 52W High-54.45% Beta0.87
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin81.50% 52W Low1.05% ATR3.11
Employees360 Current Ratio7.70 Sales Q/Q21746.20% Oper. Margin- RSI (14)29.70 Volatility5.74% 6.06%
OptionableYes Debt/Eq0.77 EPS Q/Q220.50% Profit Margin- Rel Volume0.77 Prev Close45.10
ShortableYes LT Debt/Eq0.77 EarningsFeb 26 AMC Payout- Avg Volume1.35M Price45.30
Recom2.00 SMA20-15.67% SMA50-19.34% SMA200-32.67% Volume1,036,375 Change0.44%
Feb-22-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-22-18Upgrade Evercore ISI In-line → Outperform
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
Aug-17-17Initiated Evercore ISI In-line $73
Jul-07-17Initiated Gabelli & Co Buy $125
Jun-23-17Initiated Oppenheimer Perform
Jun-20-17Upgrade Janney Neutral → Buy
Jun-19-17Upgrade Chardan Capital Markets Sell → Neutral $36 → $50
Jun-16-17Resumed Credit Suisse Outperform
Jun-13-17Initiated Leerink Partners Outperform $85
May-17-17Upgrade JP Morgan Neutral → Overweight
Feb-03-17Downgrade Chardan Capital Markets Neutral → Sell $36
Jan-27-17Initiated BofA/Merrill Buy $74
Jan-26-17Upgrade Piper Jaffray Neutral → Overweight
Jan-23-17Reiterated Stifel Buy $52 → $86
Jan-13-17Initiated Morgan Stanley Overweight
Dec-21-16Reiterated WallachBeth Hold $22 → $49
Dec-20-16Upgrade Chardan Capital Markets Sell → Neutral $15 → $36
Oct-25-16Initiated Chardan Capital Markets Sell $15
Apr-24-18 04:15PM  Clovis Oncology to Announce First Quarter 2018 Financial Results and Host Webcast Conference Call on May 8 Business Wire
Apr-17-18 08:10AM  Todays Research Reports on Stocks to Watch: Clovis Oncology and Loxo Oncology ACCESSWIRE
Apr-16-18 08:54PM  Clovis Oncology Announces Pricing of Public Offerings of Convertible Senior Notes and Common Stock Business Wire -10.27%
06:44AM  Clovis Oncology Announces Proposed Offerings of Convertible Senior Notes and Common Stock Business Wire
Apr-10-18 08:30AM  Todays Research Reports on Trending Tickers: Clovis Oncology and Nektar Therapeutics ACCESSWIRE
Apr-09-18 09:54AM  Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy Zacks +5.89%
08:47AM  Clovis Oncology (CLVS) Surges: Stock Moves 5.9% Higher Zacks
08:30AM  Todays Research Reports on Trending Tickers: Clovis Oncology and CVS Health ACCESSWIRE
Apr-06-18 04:57PM  Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval American City Business Journals +5.85%
04:12PM  Clovis Pops After Cancer Drug Gets OK; Smaller Players Crash Investor's Business Daily
01:38PM  Rubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer Business Wire
Mar-28-18 09:05AM  Why Is Clovis (CLVS) Down 9.3% Since its Last Earnings Report? Zacks
Mar-27-18 08:31PM  Tesaro Wants a Stronger Grip in Ovarian Cancer Motley Fool
04:21PM  Tesaro Sinks After Unveiling Results Of Merck-Tied Ovarian Cancer Study Investor's Business Daily
Mar-26-18 09:40AM  Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug Zacks
Mar-23-18 10:08AM  Loss-Making Clovis Oncology Inc (NASDAQ:CLVS) Expected To Breakeven Simply Wall St.
09:16AM  EMA panel for conditional OK to Clovis's ovarian cancer drug Reuters
08:52AM  Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe Business Wire
08:50AM  CHMP Grants Positive Opinion for Clovis Oncologys Rubraca® (rucaparib) Tablets Business Wire
Mar-20-18 08:10AM  Clovis Oncology, Analysts Review and Target Price, PDUFA Date, Milestones and Catalysts ACCESSWIRE
Mar-15-18 05:21PM  Edited Transcript of CLVS earnings conference call or presentation 26-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-09-18 07:44PM  AstraZeneca Goes Up Against 2 Cancer Upstarts Motley Fool
Mar-08-18 08:00AM  Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035 Business Wire
Mar-07-18 04:05PM  Clovis Oncology to Present at the Barclays Global Healthcare Conference Business Wire
08:10AM  Research Report Identifies Tapestry, Burlington Stores, GoDaddy, Clovis Oncology, Darden Restaurants, and General Cable with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-28-18 08:44AM  Clovis Oncology (CLVS) Soars: Stock Adds 6.6% in Session Zacks
08:20AM  Todays Research Reports on Trending Tickers: Clovis Oncology and Exact Sciences ACCESSWIRE
Feb-27-18 04:27PM  These Biotechs Diverge After Biggest Moneymakers Lag Expectations Investor's Business Daily +6.56%
09:08AM  Clovis (CLVS) Q4 Loss Narrower Than Expected, Revenues Miss Zacks
07:10AM  Sierra Oncology Reports 2017 Year End Results CNW Group
Feb-26-18 05:25PM  Clovis reports 4Q loss Associated Press
04:05PM  Clovis Oncology Announces 2017 Operating Results Business Wire
12:30PM  Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
11:23AM  Is There An Opportunity With Clovis Oncology Incs (NASDAQ:CLVS) 32.36% Undervaluation? Simply Wall St.
Feb-22-18 08:43AM  Is a Surprise Coming for Clovis Oncology (CLVS) This Earnings Season? Zacks +9.01%
Feb-21-18 05:10PM  Clovis Oncology Receives Positive Trend Vote from CHMP in European Regulatory Review for Rucaparib Ovarian Cancer Treatment Indication Business Wire
Feb-12-18 04:05PM  Clovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26 Business Wire
Jan-22-18 09:42AM  AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan Zacks +6.89%
Jan-12-18 08:20AM  Todays Research Reports on Trending Tickers: Clovis Oncology and Incyte Corporation ACCESSWIRE
Jan-05-18 04:39PM  Why These 3 Biotech Stocks Could Outperform Their Peers In 2018 Investor's Business Daily
Jan-04-18 08:00AM  Clovis Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-02-18 08:04AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Dec-28-17 09:10AM  Clovis Up More Than 50% in 2017: What's Driving the Stock? Zacks
Dec-19-17 08:00AM  Rucaparib MAA for the Ovarian Cancer Treatment Indication Referred by CHMP to Scientific Advisory Group on Oncology for Review Expected in February 2018 Business Wire
Dec-15-17 03:00AM  Clovis Oncology Shows Rising Relative Strength; Still Shy Of Key Threshold Investor's Business Daily
Dec-13-17 12:41PM  Value Biotech ETFs to Buy Now Zacks
Dec-06-17 03:09PM  Clovis' sNDA for Rubraca Gets Priority Review in the U.S. Zacks
02:08PM  Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down Investor's Business Daily
09:30AM  Clovis Up On Priority Review Status for Ovarian Cancer Therapy -- Biotech Movers TheStreet.com
09:30AM  Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover TheStreet.com
07:46AM  Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data Zacks
Dec-05-17 08:25PM  Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug American City Business Journals
04:05PM  Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application Business Wire
Nov-28-17 11:58AM  Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte Forbes
Nov-27-17 08:04AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Nov-24-17 11:24AM  3 Companies Competing to Gain Lead in Ovarian Cancer Market Zacks
Nov-21-17 10:25AM  TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU Zacks
08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Nov-20-17 08:20AM  Todays Research Reports on Trending Tickers: Ekso Bionics and Clovis Oncology ACCESSWIRE
Nov-15-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Nov-14-17 02:55PM  CORRECTING and REPLACING Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-13-17 06:45PM  Edited Transcript of CLVS earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
07:50AM  Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-08-17 06:40PM  Clovis Oncology to Present at the Stifel 2017 Healthcare Conference Business Wire
01:45PM  Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : November 8, 2017 Capital Cube
07:40AM  Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and Nivolumab ACCESSWIRE
Nov-02-17 11:49AM  Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss Zacks
Nov-01-17 06:26PM  Clovis reports 3Q loss Associated Press
05:47PM  Neurocrine, Exelixis, Juno Stocks Rocket After Crushing Views Investor's Business Daily
04:05PM  Clovis Oncology Announces Third Quarter 2017 Operating Results Business Wire
12:00PM  Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Oct-30-17 11:13AM  What's in the Cards for Immune Design (IMDZ) in Q3 Earnings? Zacks
Oct-26-17 12:16PM  Allergan (AGN) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-25-17 10:23AM  Clovis Oncology, Inc. Value Analysis (NASDAQ:CLVS) : October 25, 2017 Capital Cube
07:00AM  Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors CNW Group
Oct-24-17 08:14AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : October 24, 2017 Capital Cube
Oct-23-17 08:00AM  Clovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1 Business Wire
Oct-17-17 08:39AM  Gilead Sciences on the Street: Analyst Recommendations in October Market Realist
08:05AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-16-17 08:04AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-11-17 08:07AM  Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit Zacks
Oct-10-17 10:50AM  Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca Zacks
Oct-09-17 04:05PM  Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer Business Wire
Oct-06-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-05-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-04-17 11:40AM  Cancer-Cure Makers Make Great Takeover Stocks Forbes
Oct-03-17 04:22PM  These Biotechs Slump As Report Suggests Discounting Their Drugs Investor's Business Daily
Sep-28-17 03:00AM  Clovis Oncology Scores Relative Strength Rating Upgrade Investor's Business Daily
Sep-26-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Sep-25-17 08:10AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : September 25, 2017 Capital Cube
Sep-19-17 08:51AM  Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis Oncology ACCESSWIRE
Sep-18-17 04:02PM  Clovis Up 10% On Double Normal Volume Forbes +10.48%
03:44PM  So Much PARP Inhibitor Deal Hype, So Little Payoff Bloomberg
Sep-13-17 06:00AM  Clovis Oncologys Rucaparib ARIEL3 Study Data Published in The Lancet Business Wire
Sep-12-17 03:08PM  Should You Keep Your Portfolio Healthy with Biotech ETFs? Zacks
Sep-11-17 08:00AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology ACCESSWIRE
06:30AM  A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It Forbes
Sep-08-17 10:39AM  Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers TheStreet.com -7.12%
Sep-07-17 06:05PM  Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017 Business Wire
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company's product candidates include lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors; and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; collaboration and license agreement with Les Laboratoires Servier; a clinical collaboration with Bristol-Myers Squibb Company; a partnership with Foundation Medicine, Inc; and a diagnostic collaboration with Myriad Genetics, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPICKSCHEN THORLEFDirectorApr 09Sale60.024,500270,0907,618Apr 09 06:28 PM
SPICKSCHEN THORLEFDirectorMar 08Sale61.474,500276,61512,118Mar 09 08:34 PM
SPICKSCHEN THORLEFDirectorFeb 22Sale60.004,500270,00016,618Feb 23 05:14 PM
IVERS-READ GILLIAN CSee RemarksFeb 15Sale54.093,000162,270180,571Feb 16 07:54 PM
IVERS-READ GILLIAN CSee RemarksJan 16Sale59.163,000177,480183,571Jan 17 04:45 PM
SPICKSCHEN THORLEFDirectorJan 08Sale64.974,500292,36521,118Jan 09 04:45 PM
IVERS-READ GILLIAN CSee RemarksDec 15Sale64.163,000192,480182,583Dec 18 04:45 PM
SPICKSCHEN THORLEFDirectorDec 08Sale60.004,500270,00025,618Dec 08 09:32 PM
IVERS-READ GILLIAN CSee RemarksNov 15Sale63.703,000191,100185,583Nov 16 04:45 PM
IVERS-READ GILLIAN CSee RemarksOct 16Sale84.543,000253,620188,583Oct 17 08:13 PM
IVERS-READ GILLIAN CSee RemarksSep 15Sale69.503,000208,500191,583Sep 18 04:35 PM
IVERS-READ GILLIAN CSee RemarksAug 15Sale70.053,000210,150194,583Aug 15 04:53 PM
BLAIR JAMES CDirectorAug 04Sale78.6118,4501,450,35517,056Aug 08 04:03 PM
IVERS-READ GILLIAN CSee RemarksJul 17Sale91.563,000274,680197,583Jul 17 06:07 PM
IVERS-READ GILLIAN CSee RemarksJun 15Sale61.823,000185,460200,583Jun 15 05:42 PM
IVERS-READ GILLIAN CSee RemarksMay 15Sale47.393,000142,170203,583May 15 06:24 PM